Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100

Vancouver, Canada, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that Tel Aviv Sourasky Medical Center (“TASMC”), one of Israel’s top-tier academic medical centers, has officially kicked off patient enrollment by successfully recruiting the first participant for Clearmind’s FDA-approved multinational Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder (AUD).

Read more at globenewswire.com